Abstract P1-19-08: Neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT ‘basket’ trial
Year: 2020
Type: conference-abstract
Source: Cancer Research
Authors: Hans Wildiers, Valentina Boni, Cristina Saura, Mafalda Oliveira, Komal Jhaveri, Helen Won, François-Clément Bidard, Adam M Brufsky, Mark E Burkard, Andrés Cervantes, Carlos Fernández-Martos, Barbara Haley, Sherene Loi, Iben Spanggaard, Stefano Panni, Janice Lu, Melanie E Dujka, Feng Xu, Sonia Macia, Lisa D Eli, Alshad S Lalani, Sarina Piha-Paul, Funda Meric-Bernstam, David B Solit, David M Hyman
Institutions: Universitair Ziekenhuis Leuven, Vall d'Hebron Hospital Universitari, Solti, Vall d'Hebron Institute of Oncology, Memorial Sloan Kettering Cancer Center, Institut Curie, Magee-Womens Hospital, University of Wisconsin–Madison, Universitat de València, Hospital Clínico Universitario de Valencia, Fundación Instituto Valenciano de Oncología, Harold C. Simmons Comprehensive Cancer Center, Peter MacCallum Cancer Centre, Copenhagen University Hospital, Rigshospitalet, Istituti Ospitalieri di Cremona, USC Norris Comprehensive Cancer Center, Puma Biotechnology (United States), Pivotal (Spain), The University of Texas MD Anderson Cancer Center
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3013159172